• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Chair, Scientific Advisory Brd Wang Xiaodong sold $9,333,272 worth of American Depositary Shares (41,760 units at $223.50) and exercised 41,760 units of American Depositary Shares at a strike of $6.50 (SEC Form 4)

    5/15/25 5:37:59 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Wang Xiaodong

    (Last) (First) (Middle)
    C/O MOURANT GOVERNANCE SERVICES (CAYMAN)
    94 SOLARIS AVENUE

    (Street)
    CAMANA BAY, GRAND CAYMAN E9 KY1-1108

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BeiGene, Ltd. [ BGNE ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) X Other (specify below)
    Chair, Scientific Advisory Brd
    3. Date of Earliest Transaction (Month/Day/Year)
    05/13/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Ordinary Shares 5,082,165 D
    Ordinary Shares 1,025,063 I See Footnote(1)
    Ordinary Shares 3,953,100 I See Footnote(2)
    Ordinary Shares 50 I See Footnote(3)
    American Depositary Shares(4) 05/13/2025 M 41,760 A $6.5 41,760 D
    American Depositary Shares(4) 05/13/2025 S(5) 10,221 D $222.8257(6) 31,539 D
    American Depositary Shares(4) 05/13/2025 S(5) 21,235 D $223.4091(7) 10,304 D
    American Depositary Shares(4) 05/13/2025 S(5) 10,104 D $224.3213(8) 200 D
    American Depositary Shares(4) 05/13/2025 S(5) 200 D $225.68 0 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Share Option (Right to Buy) $0.5 05/13/2025 M 542,880 (9) 07/19/2025 Ordinary Shares 542,880 $0 542,887 D
    Explanation of Responses:
    1. These securities are held by a family trust, the beneficiaries of which are the Reporting Person's family members, for which the Reporting Person disclaims beneficial ownership.
    2. These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.
    3. These securities are held by the spouse of the Reporting Person.
    4. Each American Depositary Share represents 13 Ordinary Shares.
    5. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024.
    6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.03 to $223.02, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
    7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.03 to $224.02, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
    8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.03 to $224.77, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
    9. These securities vest over a five-year period as follows: 20% on July 19, 2016, and the remaining in 48 successive equal monthly installments, subject to continued service. The expiration date of the share option is July 19, 2025.
    Remarks:
    /s/ Qing Nian, as Attorney-in-Fact 05/15/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ONC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ONC

    DatePrice TargetRatingAnalyst
    4/7/2025$312.00Outperform
    RBC Capital Mkts
    3/3/2025$207.00 → $320.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $ONC
    Financials

    Live finance-specific insights

    See more
    • BeiGene Announces First Quarter 2025 Financial Results and Business Updates

      First quarter 2025 total revenues increased 49% to $1.1 billion with BRUKINSA® (zanubrutinib) global sales increasing 62% to $792 million on strong demand growth versus first quarter 2024 Achieved GAAP profitability and significantly improved operating cash flow Advanced late-stage hematology and solid tumor pipelines with plan to host Investor R&D Day on June 26 Secured shareholder approval to rename the Company to BeOne Medicines Ltd. and redomicile to Switzerland BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025.

      5/7/25 6:00:00 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene to Announce First Quarter 2025 Financial Results on May 7

      BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on Wednesday, May 7, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The conference call will be webcast live and a link to the webcast can be accessed from the investors section of the Company's website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the schedul

      4/17/25 6:01:00 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

      Total global revenues of $1.1 billion and $3.8 billion for the fourth quarter and full year, increases of 78% and 55%, respectively; narrowed GAAP operating loss and achieved full-year positive non-GAAP operating income Global BRUKINSA revenues of $828 million and $2.6 billion for the fourth quarter and full year, increases of 100% and 105%, respectively; progressed pivotal-stage programs for BCL2 inhibitor sonrotoclax and BTK CDAC BGB-16673 Advanced six and 13 New Molecular Entities (NMEs) into the clinic in the fourth quarter and full year, respectively; anticipate multiple data readouts for innovative solid tumor programs in 1H 2025 Full year 2025 revenue guidance of $4.9 billi

      2/27/25 6:00:00 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RBC Capital Mkts initiated coverage on BeiGene with a new price target

      RBC Capital Mkts initiated coverage of BeiGene with a rating of Outperform and set a new price target of $312.00

      4/7/25 8:43:36 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene upgraded by BofA Securities with a new price target

      BofA Securities upgraded BeiGene from Neutral to Buy and set a new price target of $320.00 from $207.00 previously

      3/3/25 7:35:01 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA's Leadership and Next-Generation Innovation

      Data across 31 abstracts illustrate BeiGene's deep commitment to transforming treatment for B-cell malignancies Four oral presentations highlight updated data from investigational BTK protein degrader BGB-16673 and BCL2 inhibitor sonrotoclax across a range of B-cell malignancies BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-cl

      5/14/25 4:05:00 PM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

      BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will participate in the RBC Capital Markets Global Healthcare Conference on May 20, 2025, with a fireside chat at 10 a.m. EDT. The live webcast of this event can be accessed from the investors section of the Company's website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. An archived replay will be available for 1 year following the event. About BeiGene BeiGene, which will change its name to BeOne Medicines, is a global oncology company that is discovering and developing innovative treatments that are m

      5/13/25 6:01:00 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene Announces First Quarter 2025 Financial Results and Business Updates

      First quarter 2025 total revenues increased 49% to $1.1 billion with BRUKINSA® (zanubrutinib) global sales increasing 62% to $792 million on strong demand growth versus first quarter 2024 Achieved GAAP profitability and significantly improved operating cash flow Advanced late-stage hematology and solid tumor pipelines with plan to host Investor R&D Day on June 26 Secured shareholder approval to rename the Company to BeOne Medicines Ltd. and redomicile to Switzerland BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025.

      5/7/25 6:00:00 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONC
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by BeiGene Ltd.

      SCHEDULE 13G/A - BeiGene, Ltd. (0001651308) (Subject)

      5/13/25 5:53:18 PM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene Ltd. filed SEC Form 8-K: Unregistered Sales of Equity Securities

      8-K - BeiGene, Ltd. (0001651308) (Filer)

      5/13/25 4:03:24 PM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by BeiGene Ltd.

      10-Q - BeiGene, Ltd. (0001651308) (Filer)

      5/7/25 6:09:04 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chair, Scientific Advisory Brd Wang Xiaodong sold $9,333,272 worth of American Depositary Shares (41,760 units at $223.50) and exercised 41,760 units of American Depositary Shares at a strike of $6.50 (SEC Form 4)

      4 - BeiGene, Ltd. (0001651308) (Issuer)

      5/15/25 5:37:59 PM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Oyler John exercised 4,055,415 units of Ordinary Shares at a strike of $0.50 and covered exercise/tax liability with 1,990,603 units of Ordinary Shares, increasing direct ownership by 34% to 8,163,437 units (SEC Form 4)

      4 - BeiGene, Ltd. (0001651308) (Issuer)

      5/13/25 5:24:25 PM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chair, Scientific Advisory Brd Wang Xiaodong exercised 41,760 units of American Depositary Shares at a strike of $6.50 and sold $10,133,595 worth of American Depositary Shares (41,760 units at $242.66) (SEC Form 4)

      4 - BeiGene, Ltd. (0001651308) (Issuer)

      4/16/25 5:12:21 PM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care